Arvinas Inc

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why You Shouldn't Bet Against Arvinas (ARVN) Stock

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Arvinas, Inc. (ARVN) Upgraded to Buy: What Does It Mean for the Stock?

As of late, it has definitely been a great time to be an investor in Arvinas.

Will Arvinas Continue to Surge Higher?

Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience

Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors

Dropbox

Trinity Industries

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys In The Past Week: Arvinas, Dropbox, Trinity

NEW HAVEN, Conn., Nov.  06, 2019  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of $22.00 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to an additional 681,818 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by Arvinas.

Arvinas, Inc. Announces Pricing of Public Offering of Common Stock

Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Arvinas, Inc. (ARVN) Upgraded to Strong Buy: Here's Why

Biogen

Can these recent highfliers keep climbing?

2 Biotech Stocks That Soared Last Week

-Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers

Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders

NEW HAVEN, Conn., Oct.  17, 2019  (GLOBE NEWSWIRE) -- Arvinas Inc., (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will be participating in multiple sessions of the 2nd Targeted Protein Degradation Summit.  In one of these sessions, Ian Taylor, Ph.D., Chief Scientific Officer at Arvinas, will share an update on the company’s PROTAC® protein degrader platform, including initial safety, tolerability, and pharmacokinetic data from Arvinas’ ongoing Phase 1 clinical trials of ARV-110 and ARV-471.

Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit

NEW HAVEN, Conn., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new thought leaders will join the company’s scientific advisory board (SAB). The new members are Tomasz M. Beer, M.D., F.A.C.P., Adam L. Boxer, M.D., Ph.D., Sara Courtneidge, Ph.D., Lennart Mucke, M.D., Benjamin G. Neel, M.D., Ph.D., and Lillian L. Siu, M.D.

Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders

Arvinas Inc's (NASDAQ: ARVN) two lead assets have a “high likelihood of success” in their respective indications, according to Wedbush.

Wedbush Starts Arvinas At Outperform, Says Lead Assets Could Have Successful Trials

Trial is evaluating the safety and tolerability of ARV-471 in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer Trial is evaluating the safety and tolerability of ARV-471 in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer

Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader

Shares are trading at a 10% discount to IPO price point, and current weakness is attributable to lockup expiration.

Arvinas: Early-Stage Research In An Exciting Field, Worthy Of Entry?

News for Arvinas Inc Stock (ARVN)